Association between Pentraxin-3 and Cardiac Troponin-I with Left Ventricular Systolic Function in Patients with Anterior ST-Segment Elevation Myocardial Infarction: Evaluation by Speckle Tracking Echocardiography

摘要

Background: Pentraxin 3 is an inflammatory biomarker whose serum level is increased during acute myocardial infarction (AMI). The aim of this study was to measure the serum pentraxin-3 level in anterior ST-segment elevation myocardial infarction (STEMI), to investigate correlation with the left ventricular (LV) systolic function assessed by speckle tracking echocardiography, and compare with the well-established cardiac biomarkers of myocardial injury such as troponin-I. Methods: Serum pentraxin-3 level was measured by ELISA in 50 patients with anterior STEMI. LV strain was measured by speckle tracking echocardiography. The results were compared to twenty sex- and age-matched persons who had history of stable angina and normal LV ejection fraction (LVEF). Results: Serum level of pentraxin-3 was significantly higher in STEMI patients in comparison to the control group (8.3 ± 3.1 versus 3.4 ± 1.2 ng/ml, p 0.001). Average LV global longitudinal strain (GLS) was reduced in STEMI patients in comparison to control subjects (11.2 ± 2.4 versus 20.2 ± 2.1, p 0.001). In addition, there was a significant negative correlation between serum pentraxin-3 level and LVEF (r = -0.557, p 0.001) and the average LVGLS (r =-0.529, p 0.001). Serum pentraxin-3 cutoff value > 8.3 ng/ml had sensitivity of 81.8% and specificity of 86.4% to detect LVEF less than 50% (p 0.001). While, peak cardiac troponin-I level > 34 ng/ml was 86% sensitive to detect LVEF less than 50% with specificity of 90.9%. Conclusions: The elevated serum level of pentraxin-3 and cardiac troponin-I in STEMI patients and their association with both LVEF and GLS support the concept that the magnitude of these biomarkers correlates to the severity of myocardium injury.